-
Mashup Score: 0Press releases | GSK US - 8 day(s) ago
Keep up to date with our news and recent announcements
Source: us.gsk.comCategories: General Medicine NewsTweet
-
Mashup Score: 2Home | GSK - 3 month(s) ago
At GSK, we unite science, technology and talent to get ahead of disease together
Source: www.gsk.comCategories: General Medicine News, PayerTweet-
RT @GSK: Explore the key data from our strong 2024 performance. More information for media and investors: https://t.co/75VTwX9yp5 $GSK
-
-
Mashup Score: 1Take action | World Cancer Day - 3 month(s) ago
Get involved any way you can. Spread the word. Take action. Because together, we can create change.
Source: www.worldcancerday.orgCategories: General Medicine News, PayerTweet-
Today is #WorldCancerDay! We stand with the @uicc in their mission to #CloseTheCareGap and reduce the burden of cancer by taking action to help solve inequities in diagnosis and treatment. Learn more and discover ways to get involved: https://t.co/TwMa71YR5D https://t.co/cHjot9RZcS
-
-
Mashup Score: 0Home - 3 month(s) ago
The can’t miss event presented by Fierce Pharma & Fierce Biotech, running in tandem with the J.P. Morgan Healthcare Conference covering the biggest topics facing the industry.
Source: www.fiercejpmweek.comCategories: General Medicine News, PayerTweet-
Today at #JPM25: Hesham Abdullah, Senior Vice President, Global Head Oncology, R&D, joins the #FierceJPMWeek ‘Future of Oncology’ panel to explore how advanced research and innovative treatments are reimagining patient care. For #investors and #media: https://t.co/WIgUcBtigN
-
-
Mashup Score: 0Home | GSK - 3 month(s) ago
At GSK, we unite science, technology and talent to get ahead of disease together
Source: www.gsk.comCategories: General Medicine News, PayerTweet-
We look forward to joining the @jpmorgan Healthcare Conference next week, sharing how the breadth of our portfolio, positive pipeline data and focus on science tech, and culture are helping us deliver sustained profitable growth. 🔗 https://t.co/eO7rQehXCG #JPM2025 #JPM25
-
-
Mashup Score: 0GSK’s Shingrix new prefilled syringe presentation accepted for review by US FDA | GSK US - 3 month(s) ago
If approved, the new presentation will offer a convenient administration option to healthcare professionals.
Source: us.gsk.comCategories: General Medicine News, PayerTweet-
News for #Media and #Investors: The FDA has accepted for review our application for a new presentation of SHINGRIX: https://t.co/IHbhmd5h6P https://t.co/nmIbxYEryG
-
-
Mashup Score: 0Jemperli (dostarlimab-gxly) receives US FDA Breakthrough Therapy Designation for locally advanced dMMR/MSI-H rectal cancer | GSK US - 4 month(s) ago
Designation based on data showing no evidence of disease in 100% of all 42 patients who completed treatment with dostarlimab-gxly.
Source: us.gsk.comCategories: General Medicine News, PayerTweet-
#News for #Investors and #Media: The FDA has granted Breakthrough Therapy Designation to one of our immuno-oncology treatments. Learn more: https://t.co/bVm8UoqCfe https://t.co/rAJXo9XJ1V
-
-
Mashup Score: 0Belantamab Mafodotin shows significant overall survival benefit, reducing the risk of death by 42% in multiple myeloma at or after first relapse | GSK US - 5 month(s) ago
DREAMM-7 trial shows sustained overall survival benefit for belantamab mafodotin combination versus daratumumab combination.
Source: us.gsk.comCategories: General Medicine News, PayerTweet-
#News for #Investors and #Media: Today at #ASH24, we presented positive results from our phase III clinical trial evaluating one of our #bloodcancer treatments. Learn more: https://t.co/AwZrdtqB0q https://t.co/boMzOULmqp
-
-
Mashup Score: 3US FDA accepts GSK’s submission for the use of Nucala (mepolizumab) in COPD | GSK US - 5 month(s) ago
Nucala could be the first approved biologic with monthly dosing for patients with COPD
Source: us.gsk.comCategories: General Medicine News, PayerTweet-
#News for #investors and #media: Today we have announced the FDA has accepted the submission for one of our biologics in chronic obstructive pulmonary disease (#COPD). Learn more here: https://t.co/BBElA0p6Ij https://t.co/z5SRDDMLhf
-
-
Mashup Score: 3Belantamab mafodotin combinations accepted for review by the US FDA for the treatment of relapsed/refractory multiple myeloma | GSK US - 5 month(s) ago
Regulatory submission supported by phase III head-to-head DREAMM-7 and DREAMM-8 trials showing statistically significant efficacy.
Source: us.gsk.comCategories: General Medicine News, PayerTweet-
#News for #Investors and #Media: The @US_FDA has accepted our application for one of our #bloodcancer therapies in combination with standards of care. Learn more: https://t.co/X58XIBjc7P https://t.co/GDOmI3eTvl
-
#News for #Media and #Investors Two of our vaccines have received new recommendations from the US Advisory Committee on Immunization Practices (ACIP). These recommendations will be reviewed for official adoption. Learn more at: https://t.co/9Mli0Jol76 https://t.co/b95T3jArGa